. 2018 Feb 5;2(3):263–270. doi: 10.1182/bloodadvances.2017012005

Table 2.

Anti-HLA antibodies in patients who underwent haplo-HCT

Number	Graft type	Anti-HLA antibodies		Donor-specific anti-HLA antibodies		Outcome
Number	Graft type	Class I	Class II	Class I	Class II	Outcome
1	CD34⁺ selected^*	No	No	No	No	Stable
2	CD34⁺ selected	No	No	No	No	Rejection
3	CD34⁺ selected	No	No	No	No	Rejection
4	CD34⁺ selected	No	No	No	No	Stable
5	CD34⁺ selected	No	Yes	No	No	Rejection
6	CD34⁺ selected	No	Yes	No	No	Stable
7	CD34⁺ selected	No	No	No	No	Stable
8	CD34⁺ selected	Yes	Yes	A24; MFI = 21 520	No	Rejection
9	CD34⁺ selected	Yes	No	B57; MFI = 777	No	Rejection
10	CD34⁺ selected	No	No	No	No	Stable
11	CD34⁺ selected	No	No	No	No	Rejection
12	CD34⁺ selected	No	No	No	No	Stable
13	CD34⁺ selected	Yes	Yes	A23; MFI=16891	DQ2; MFI = 2358	Rejection
13	CD34⁺ selected	Yes	Yes	B45; MFI = 21 993	DQ2; MFI = 2358	Rejection
14	TCRαβ depleted^†	No	No	No	No	Stable
15	TCRαβ depleted	Yes	Yes	No	No	Rejection
16	TCRαβ depleted	No	No	No	No	Stable
17	TCRαβ depleted	No	No	No	No	Stable
18	TCRαβ depleted	No	No	No	No	Stable

“No” indicates that antibodies were not found.

MFI, mean fluorescence intensity.

CD34⁺-selected and/or CD3⁺/19⁺-depleted grafts.

^†

TCRαβ⁺/CD19⁺-depleted grafts.